kt 3283
Alternative Names: kt 3283 dual action DNA Damage Response inhibitors - Rakovina Therapeutics; Kt-3283Latest Information Update: 30 May 2023
At a glance
- Originator Rakovina Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA repair inhibitors; Histone deacetylase inhibitors; Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ewing's sarcoma
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and pharmacokinetic data from preclinical studies in Ewing's sarcoma was presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Nov 2022 Pharmacodynamics data from preclinical studies in Ewing's sarcoma released by Rakovina Therapeutics
- 11 May 2022 Preclinical trials in Ewing's Sarcoma in Canada (unspecified route)